Supplementary Table S1. Treatment-Emergent Adverse Events and Vital Signs (Efficacy Analyses Data Set)

Treatment-emergent adverse events (occurring in ≥5% of patients in any edivoxetine group and twice the rate in placebo group)	*Placebo (%)* n=*63*	*Edivoxetine 0.1 (%)* n=*60*	*Edivoxetine 0.2 (%)* n=*60*	*Edivoxetine 0.3 (%)* n=*61*
Upper abdominal pain	9.5	23.3*	5.0	14.8
Vomiting	4.8	8.3	15.0	14.8
Decreased appetite	4.8	10.0	13.3	9.8
Nausea	6.3	8.3	15.0	9.8
Fatigue	1.6	5.0	3.3	4.9
Sedation	1.6	1.7	8.3	4.9
Somnolence	7.9	5.0	20.0	4.9
Constipation	0.0	3.3	5.0	3.3
Abdominal pain	0.0	0.0	5.0	1.6
Diarrhea	3.2	6.7	3.3	1.6
Nasal congestion	1.6	0.0	5.0	1.6
Altered mood	1.6	1.7	5.0	0.0
Vital signs, weight, and height				
LS mean change from baseline to week 8				
Weight (kg)	1.4	−0.03*	0.3*	−0.3*
Height (cm)	0.8	0.9	0.7	0.6
Pulse (bpm) sitting	−1.7	6.7*	12.0*	11.8*
Diastolic BP (mmHg) sitting	−0.9	5.0*	6.4*	4.5*
Systolic BP (mmHg) sitting	0.2	5.1*	5.1*	4.2*
Percentage of patients with a categorical shift in BP at any time				
Sitting diastolic BP increase ≥5 mm Hg and ≥95th percentile	6.3	17.2	25.0*	22.0*
Sitting systolic BP increase ≥5 mm Hg and ≥95th percentile	14.3	22.4	28.3	13.6

*$p < 0.05$ vs. placebo.
0.1 = 0.1 mg/kg; 0.2 = 0.2 mg/kg; 0.3 = 0.3 mg/kg.
BP, blood pressure; LS, least squares; QTc = corrected QT interval.